Ture BxPC-3 cell BxPC-3 cell BxPC-3 cell BxPC-3 cell BxPC-3 cell
Ture BxPC-3 cell BxPC-3 cell BxPC-3 cell BxPC-3 cell BxPC-3 cell MiaPACA-2 and PANC-1 cells BxPC-3 cell BxPC-3 cell BxPC-3 cell BxPC-3 cell BxPC-3 cell BxPC-3 cell BxPC-3 cell MiaPACA-2, PANC-1 and BxPC-3 cells BxPC-3 cell MiaPACA-2, PANC-1 and BxPC-3 cells BxPC-3 cell Human PDAC Tissues and PDAC Cell LinesReference [16] [16] [16] [16] [16] [15] [16] [16] [16] [16] [16] [16] [16] [15,16] [16] [15,16] [16] [22]up up up up up up up up up up up up up up up up up up up up down down downmiR-424-5p down miR-17-5p miR-203 miR-29c-3p miR-adown down up up14 pancreatic cancer cell lines (AsPC-1, KP-1 N, KP-3 and PANC-1 et al.) [11] BxPC-3 cell normal pancreas and PDAC tissue [16] [30]miR-615-5p upBxPC-3, CFPAC-1, SW1990 and PANC-[31]Regulation reported in pancreatic cancer tissues/cells compared with normal pancreatic tissues/cells from the literature.Gui et al. BMC Complementary and Alternative Medicine (2015) 15:Page 6 ofthe 2-CT method [10]. All assays were performed in triplicate.Statistical analysisA log2 fold change [log2 (oridonin/control)] was used to define differentially expressed miRNAs, and Student’s ttest was employed to calculate P values. The target genes were analysed in terms of the annotation of their Gene Ontology (GO) categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using Fisher’s exact test. Results of realtime RT-PCR experiments are expressed as means ?standard deviation (SD). Statistical comparisons were performed with the SPSS 17.0 software (Univariate Analysis of Variance) and statistical significance was considered for P values lower than 0.05.up-regulated by oridonin. Among them, there are many new miRNAs whose function has been scarcely described in the literature. Previous studies related to miRNA AZD-8055 supplier expression in human pancreatic cancer are collected and summarised in Table 2 for comparison and discussion. Results showed that the expression of some miRNAs was changed dramatically after treatment with oridonin, as shown in Table 3 (20 miRNAs, including miR-205, miR-10b, miR-125b, PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/27488460 miR200b, miR-132, miR-320, miR-185, miR-424-5p, and miR-17-5p), which indicated that oridonin may influence BxPC-3 pancreatic cancer cells through regulating miRNAs, though verifying this hypothesis will require further investigation.ResultsMiRNA expression was altered in BxPC-3 cells treated with oridoninTarget prediction and GO and KEGG pathway analysesTo study the responses of miRNAs to oridonin, microarray analysis of miRNA expression in BxPC-3 cells treated with oridonin was compared with the expression of miRNAs in DMSO treated cells. Only miRNAs showing significant expression among the oridonin treatments and their controls are reported (Table 1). As shown in Table 1, 105 reporters presented a strong response (signal reading >500, p 0.01, |Log2-valueb| 1) and significant regulation. Among these 105 miRNAs, 49 miRNAs were significantly down-regulated, whereas 56 were significantlyIt has been demonstrated that one miRNA could target more than one gene, whereas some genes were targets of more than one miRNA. To predict the target mRNAs of the differentially expressed miRNAs, we performed target prediction for the differentially expressed miRNAs identified in the BxPC-3 cells using three different types of PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/26780312 online software: TargetScan, PicTar and miRanda. The intersection of three software’s predictions was taken as the finally potential target genes. GO and KEGG pathway analyses were performed on the target genes of the.